Lido Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.21M Buy
10,877
+6,009
+123% +$2.23M 0.01% 544
2026
Q1
$1.43M Buy
4,868
+8
+0.2% +$2.63K ﹤0.01% 814
2025
Q4
$1.58M Buy
4,860
+510
+12% +$172K ﹤0.01% 799
2025
Q3
$1.41M Sell
4,350
-917
-17% -$285K ﹤0.01% 806
2025
Q2
$2.05M Buy
5,267
+113
+2% +$45.5K 0.01% 582
2025
Q1
$2.24M Buy
5,154
+805
+19% +$323K 0.01% 515
2024
Q4
$1.6M Sell
4,349
-320
-7% -$134K 0.01% 588
2024
Q3
$2.43M Buy
4,669
+515
+12% +$275K 0.01% 425
2024
Q2
$2.25M Buy
4,154
+563
+16% +$298K 0.01% 425
2024
Q1
$1.86M Buy
3,591
+107
+3% +$53.2K 0.01% 443
2023
Q4
$1.64M Buy
3,484
+50
+1% +$23.1K 0.01% 465
2023
Q3
$1.5M Buy
3,434
+317
+10% +$144K 0.01% 442
2023
Q2
$1.38M Buy
3,117
+622
+25% +$287K 0.01% 453
2023
Q1
$1.15M Sell
2,495
-162
-6% -$77.1K 0.01% 445
2022
Q4
$1.36M Buy
2,657
+40
+2% +$20.3K 0.02% 350
2022
Q3
$1.19M Sell
2,617
-215
-8% -$103K 0.01% 334
2022
Q2
$1.37M Buy
2,832
+68
+2% +$33.6K 0.02% 284
2022
Q1
$1.36M Buy
2,764
+728
+36% +$333K 0.02% 333
2021
Q4
$943K Sell
2,036
-189
-8% -$79.5K 0.01% 431
2021
Q3
$829K Buy
2,225
+589
+36% +$224K 0.01% 449
2021
Q2
$625K Buy
1,636
+258
+19% +$98.6K 0.01% 481
2021
Q1
$495K Buy
1,378
+175
+15% +$56.3K 0.01% 502
2020
Q4
$386K Buy
1,203
+56
+5% +$17.2K 0.01% 547
2020
Q3
$308K Buy
1,147
+88
+8% +$23.7K 0.01% 478
2020
Q2
$279K Buy
1,059
+4
+0.4% +$1.07K 0.01% 465
2020
Q1
$240K Buy
1,055
+38
+4% +$10.4K 0.01% 473
2019
Q4
$307K Sell
1,017
-84
-8% -$23.1K 0.01% 494
2019
Q3
$264K Buy
1,101
+26
+2% +$7.12K 0.01% 481
2019
Q2
$303K Sell
1,075
-56
-5% -$15.3K 0.02% 423
2019
Q1
$324K Buy
1,131
+19
+2% +$5.5K 0.02% 368
2018
Q4
$292K Buy
1,112
+113
+11% +$31.1K 0.03% 318
2018
Q3
$273K Buy
999
+43
+4% +$11.2K 0.03% 356
2018
Q2
$227K Buy
956
+18
+2% +$4.17K 0.03% 370
2018
Q1
$206K Buy
+938
New +$220K 0.03% 361

Other funds holding ELV

Lido Advisors's ELV Position: Q2 2026 in Review

Lido Advisors increased its Elevance Health (ELV) stake by 123% in Q2 2026, buying an estimated $2.23M and bringing the position to 10,877 shares worth $4.21M. The position accounts for 0.01% of the portfolio, ranked #544.

Lido Advisors first reported a position in ELV in Q1 2018 and has held it in 34 quarters since. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Lido Advisors held 10,877 shares of Elevance Health worth $4.21M as of Q2 2026.
  • Lido Advisors bought 6,009 Elevance Health shares in Q2 2026, an estimated $2.23M.
  • Elevance Health made up 0.01% of Lido Advisors's portfolio in Q2 2026, its #544 holding.
  • Lido Advisors first reported a position in Elevance Health in Q1 2018 and has held it in 34 quarters since.
  • 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.